Author - Michelle Carr

Biocept Logo

Brookline starts Biocept at buy; PT $2.06

Brookline Capital Markets initiated coverage of Biocept (NASDAQ:BIOC) with a “buy” rating and price target of $2.06. The stock closed at 44 cents on May 13. Biocept is a molecular oncology diagnostics company that...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.